{"brief_title": "Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia", "brief_summary": "The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.", "condition": "Pneumonia", "intervention_type": "Drug", "intervention_name": "Tifacogin", "criteria": "Inclusion Criteria: - Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence - Pneumonia of sufficient severity to require ICU admission and management Exclusion Criteria: - Pregnancy - Weight over 150 kg - Patients at increased risk of bleeding - Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa - Treatment with heparin or anticipated need for heparin", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00084071.xml"}